Vertex Pharmaceuticals (VRTX) Shares Outstanding (Weighted Average) (2009 - 2026)

Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) history runs 18 years deep, the most recent figure standing at $254.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) fell 1.09% year-over-year to $254.1 million; the TTM figure through Mar 2026 stood at $254.1 million (down 1.09% YoY), while the FY2025 annual figure was $255.7 million, down 0.85% from the prior year.
• Shares Outstanding (Weighted Average) was $254.1 million for Q1 2026 at Vertex Pharmaceuticals, down from $255.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $258.2 million in Q1 2024 to a low of $254.1 million in Q1 2026.
• Historically, Shares Outstanding (Weighted Average) has averaged $256.8 million across 5 years, with a median of $256.9 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) dropped 1.66% in 2022, then climbed 0.9% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $256.1 million in 2022, then gained by 0.62% to $257.7 million in 2023, then gained by 0.08% to $257.9 million in 2024, then declined by 0.85% to $255.7 million in 2025, then slipped by 0.63% to $254.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $254.1 million (Q1 2026), $255.7 million (Q4 2025), and $256.4 million (Q3 2025), per Business Quant data.